These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23381000)

  • 1. Prostate cancer: The androgen receptor remains front and centre.
    Saylor PJ
    Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000
    [No Abstract]   [Full Text] [Related]  

  • 2. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
    Bedoya DJ; Mitsiades N
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
    J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in chemotherapy of prostate cancer.
    Heicappell R
    Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
    [No Abstract]   [Full Text] [Related]  

  • 7. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Boissier E; Loriot Y; Vignot S; Massard C
    Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
    Courtney KD; Taplin ME
    Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics.
    Comstock CE; Knudsen KE
    Cell Cycle; 2007 Jun; 6(11):1307-13. PubMed ID: 17568191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of abiraterone acetate withdrawal.
    Witjes JA
    Eur Urol; 2013 Sep; 64(3):517-8. PubMed ID: 23806520
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
    Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
    Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The androgen receptor for the radiation oncologist.
    Quero L; Rozet F; Beuzeboc P; Hennequin C
    Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate: in metastatic castration-resistant prostate cancer.
    Yang LP
    Drugs; 2011 Oct; 71(15):2067-77. PubMed ID: 21985170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
    Scott LJ; Yang LPH; Lyseng-Williamson KA
    Drugs Aging; 2012 Mar; 29(3):243-248. PubMed ID: 22372727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
    Walczak JR; Carducci MA;
    Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.
    Vaz S; Hadaschik B; Gabriel M; Herrmann K; Eiber M; Costa D
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):9-15. PubMed ID: 31654093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.